4-[(4-Methylphenyl)methoxy]pyridine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(4-Methylphenyl)methoxy]pyridine
• 化学式: C₁₃H₁₃NO
• 分子量: 199.25
• InChiKey: KUOKPCPOQSQRFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES
  申请人：Albany Molecular Research, Inc.

  公开号：US20140206696A1

  公开（公告）日：2014-07-24

  Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R 1 is H or optionally substituted alkyl; R 2 , R 3 , R 4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF 3 , and —CN; G is —CR 12 R 13 —NR 5 — or —NR 5 —CR 12 R 13 ; R 5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R 6 , —C(═O)—O—R 7 , or —C(═O)—NR 19 R 20 ; R 6 and R 7 are each optionally substituted alkyl or optionally substituted heterocycle; R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 and R 20 are each independently selected from H or optionally substituted alkyl; R 14 and R 15 are each independently H or halogen; L is —CH 2 —O—, —CH 2 CH 2 —, —CH═CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.

  用于治疗各种疾病的药物组合物中的取代吡啶吲哚对应于公式（I），其中R1为H或可选取代烷基；R2、R3、R4分别选自H、—O-烷基、—S-烷基、烷基、卤素、—CF3和—CN；G为—CR12R13—NR5—或—NR5—CR12R13；R5为H、可选取代烷基、可选取代杂环、—C（═O）—R6、—C（═O）—O—R7或—C（═O）—NR19R20；R6和R7分别为可选取代烷基或可选取代杂环；R8、R9、R10、R11、R12、R13、R19和R20分别选自H或可选取代烷基；R14和R15各自为H或卤素；L为—CH2—O—、—CH2CH2—、—CH═CH—或一个键；B为芳基或杂芳基或环烷基；但当L为直接键时，B不能是未取代的杂芳基或单取代氟的杂芳基。
• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• US9266834B2
  申请人：——

  公开号：US9266834B2

  公开（公告）日：2016-02-23
• US9296743B2
  申请人：——

  公开号：US9296743B2

  公开（公告）日：2016-03-29